Showing 3891-3900 of 5956 results for "".
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLs in the European Unionhttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols-in-the-european-union/2482610/Bausch + Lomb announced the commercial launch of the enVista Aspire monofocal and toric IOLs in the European Union after receiving a CE Mark late last year. According to B+L, enVista Aspire combines 'intermediate optimized' optics, which are designed for a broader dept
- Alkeus Announces Interim TEASE-3 Study Results Evaluating Gildeuretinol in Early-Stage Stargardt Patientshttps://modernod.com/news/alkeus-announces-new-interim-tease-3-study-results-showing-gildeuretinol-prevented-disease-progression-in-early-stage-stargardt-patients/2482608/Alkeus Pharmaceuticals announced positive interim data from its TEASE-3 study demonstrating that additional early-stage Stargardt disease patients treated with oral gildeuretinol acetate showed no disease progression, including stable visual acuity, over multiple years. “Thes
- Altris AI Introduces AI-Powered Fluid and GA Quantification Featureshttps://modernod.com/news/altris-ai-introduces-ai-powered-fluid-and-ga-quantification-features/2482606/Altris AI, which utilizes artificial intelligence for OCT scan analysis, has unveiled additional quantification features for fluids and geographic atrophy (GA) tracking on its web platform. Altris AI currently detects more than 70 retina pathologies and biomarkers. The platform'
- Atsena Therapeutics Initiates Part B of Phase 1/2 Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-initiates-part-b-of-phase-12-clinical-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482602/Atsena Therapeutics announced the initiation of Part B of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s n
- Canyon Labs Acquire's iuvo BioScience’s Lab Services and Consulting Businesseshttps://modernod.com/news/canyon-labs-acquires-iuvo-biosciences-lab-services-and-consulting-businesses/2482600/Canyon Labs, a provider of analytical & packaging lab testing and consulting for medical devices and pharmaceuticals, has acquired the laboratory services and scientific consulting divisions of iuvo BioScience, a provider of ophthalmic medical device and pharmaceutical cli
- Lumibird Medical Rebrands its Japanese Subsidiaryhttps://modernod.com/news/lumibird-medical-rebrands-its-japanese-subsidiary/2482598/Lumibird Medical has announced the rebranding of its Japanese subsidiary. Formerly known as Ellex Japan, the company will now operate under the name Lumibird Medical Japan, effective immediately. Founded in Osaka in 2003, the subsidiary has grown over the past two decades,&nbs
- Regeneron Acquires UK-Based Biotech Oxularhttps://modernod.com/news/regeneron-acquires-uk-based-biotech-oxular/2482596/Regeneron has acquired Oxular, a clinical stage company making ocular delivery technology for retinal disorders. The news of the aquisition was made from a LinkedIn
- VisionGift Announces the Retirement of Longtime Medical Director, Mark Terry, MDhttps://modernod.com/news/visiongift-announces-the-retirement-of-longtime-medical-director-mark-terry-md/2482595/VisionGift, a nonprofit dedicated ot ocular donation and corneal transplantation, announced the retirement of its medical director Mark Terry, MD, after 34 years of dedicated service to the field of eye banking. Succeeding him in this role will be Winston Chamberlain, MD, PhD, and
- Vabysmo Prefilled Syringe (PFS) Approved in the EUhttps://modernod.com/news/vabysmo-prefilled-syringe-pfs-approved-in-the-eu-for-three-retinal-conditions/2482582/The European Medicines Agency (EMA) has approved Roche's Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion
- Viridian Announces Topline Results from Veligrotug Phase 3 Trial in Patients with Chronic TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-veligrotug-phase-3-trial-in-patients-with-chronic-thyroid-eye-disease/2482580/Viridian Therapeutics announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). “We are extremely